Mirroring the effect previously observed in B16/F10 tumor-bearing mice treated intratumorally with AS1411-SMG1 AsiC, systemic administration of the AS1411-control AsiC in B16/F10 the AS141-control AsiC again showed a significant reduction in tumor progression compared with untreated mice. This evidence concerns the gene SMG1 and neoplasm.